{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T07:09:36Z","timestamp":1778742576943,"version":"3.51.4"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1007\/s10549-016-3682-6","type":"journal-article","created":{"date-parts":[[2016,1,14]],"date-time":"2016-01-14T01:32:52Z","timestamp":1452735172000},"page":"405-413","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Clinically advanced and metastatic pure mucinous carcinoma of the breast: a comprehensive genomic profiling study"],"prefix":"10.1007","volume":"155","author":[{"given":"Jeffrey S.","family":"Ross","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurie M.","family":"Gay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sahar","family":"Nozad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siraj M.","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann","family":"Boguniewicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Depinder","family":"Khaira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrienne","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia A.","family":"Elvin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo-Anne","family":"Vergilio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Suh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent A.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip J.","family":"Stephens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,1,13]]},"reference":[{"key":"3682_CR1","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1200\/JCO.1999.17.5.1442","volume":"17","author":"SG Diab","year":"1999","unstructured":"Diab SG, Clark GM, Osborne CK et al (1999) Tumor characteristics and clinical outcome of tubular and mucinous breast carcinomas. J Clin Oncol 17:1442\u20131448","journal-title":"J Clin Oncol"},{"key":"3682_CR2","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.amjsurg.2008.06.013","volume":"196","author":"CR Barkley","year":"2008","unstructured":"Barkley CR, Ligibel JA, Wong JS et al (2008) Mucinous breast carcinoma: a large contemporary series. Am J Surg 196:549\u2013551. doi: 10.1016\/j.amjsurg.2008.06.013","journal-title":"Am J Surg"},{"key":"3682_CR3","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1136\/jcp.2006.046227","volume":"61","author":"PH Tan","year":"2008","unstructured":"Tan PH, Tse GMK, Bay BH (2008) Mucinous breast lesions: diagnostic challenges. J Clin Pathol 61:11\u201319. doi: 10.1136\/jcp.2006.046227","journal-title":"J Clin Pathol"},{"key":"3682_CR4","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s10549-007-9809-z","volume":"111","author":"S Saverio Di","year":"2008","unstructured":"Di Saverio S, Gutierrez J, Avisar E (2008) A retrospective review with long term follow up of 11,400 cases of pure mucinous breast carcinoma. Breast Cancer Res Treat 111:541\u2013547. doi: 10.1007\/s10549-007-9809-z","journal-title":"Breast Cancer Res Treat"},{"key":"3682_CR5","volume-title":"Pathology and genetics of tumours of the breast and female genital organs","author":"FA Tavassoli","year":"2003","unstructured":"Tavassoli FA, Devilee P (2003) Pathology and genetics of tumours of the breast and female genital organs. IARC Press, Lyon"},{"key":"3682_CR6","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S0046-8177(86)80152-6","volume":"17","author":"F Clayton","year":"1986","unstructured":"Clayton F (1986) Pure mucinous carcinomas of breast: morphologic features and prognostic correlates. Hum Pathol 17:34\u201338","journal-title":"Hum Pathol"},{"key":"3682_CR7","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1177\/1066896907307047","volume":"16","author":"L Chen","year":"2008","unstructured":"Chen L, Fan Y, Lang R et al (2008) Breast carcinoma with micropapillary features: clinicopathologic study and long-term follow-up of 100 cases. Int J Surg Pathol 16:155\u2013163. doi: 10.1177\/1066896907307047","journal-title":"Int J Surg Pathol"},{"key":"3682_CR8","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/path.4325","volume":"232","author":"R Natrajan","year":"2014","unstructured":"Natrajan R, Wilkerson PM, Marchi\u00f2 C et al (2014) Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast. J Pathol 232:553\u2013565. doi: 10.1002\/path.4325","journal-title":"J Pathol"},{"key":"3682_CR9","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1634\/theoncologist.2008-0230","volume":"14","author":"JS Ross","year":"2009","unstructured":"Ross JS, Slodkowska EA, Symmans WF et al (2009) The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 14:320\u2013368. doi: 10.1634\/theoncologist.2008-0230","journal-title":"Oncologist"},{"key":"3682_CR10","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/000313480807400204","volume":"74","author":"JD Adair","year":"2008","unstructured":"Adair JD, Harvey KP, Mahmood A et al (2008) Recurrent pure mucinous carcinoma of the breast with mediastinal great vessel invasion: hER-2\/neu confers aggressiveness. Am Surg 74:113\u2013116","journal-title":"Am Surg"},{"key":"3682_CR11","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1136\/jcp.2010.082495","volume":"63","author":"A Ranade","year":"2010","unstructured":"Ranade A, Batra R, Sandhu G et al (2010) Clinicopathological evaluation of 100 cases of mucinous carcinoma of breast with emphasis on axillary staging and special reference to a micropapillary pattern. J Clin Pathol 63:1043\u20131047. doi: 10.1136\/jcp.2010.082495","journal-title":"J Clin Pathol"},{"key":"3682_CR12","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.amjsurg.2007.06.012","volume":"194","author":"T Vo","year":"2007","unstructured":"Vo T, Xing Y, Meric-Bernstam F et al (2007) Long-term outcomes in patients with mucinous, medullary, tubular, and invasive ductal carcinomas after lumpectomy. Am J Surg 194:527\u2013531. doi: 10.1016\/j.amjsurg.2007.06.012","journal-title":"Am J Surg"},{"key":"3682_CR13","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/bjc.1997.180","volume":"75","author":"IS Fentiman","year":"1997","unstructured":"Fentiman IS, Millis RR, Smith P et al (1997) Mucoid breast carcinomas: histology and prognosis. Br J Cancer 75:1061\u20131065","journal-title":"Br J Cancer"},{"key":"3682_CR14","doi-asserted-by":"crossref","first-page":"308","DOI":"10.4048\/jbc.2011.14.4.308","volume":"14","author":"SY Bae","year":"2011","unstructured":"Bae SY, Choi M-Y, Cho DH et al (2011) Mucinous carcinoma of the breast in comparison with invasive ductal carcinoma: clinicopathologic characteristics and prognosis. J Breast Cancer 14:308\u2013313. doi: 10.4048\/jbc.2011.14.4.308","journal-title":"J Breast Cancer"},{"key":"3682_CR15","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","volume":"490","author":"Cancer Genome Atlas Network","year":"2012","unstructured":"Cancer Genome Atlas Network (2012) Comprehensive molecular portraits of human breast tumours. Nature 490:61\u201370. doi: 10.1038\/nature11412","journal-title":"Nature"},{"key":"3682_CR16","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1634\/theoncologist.2014-0108","volume":"19","author":"MV Dieci","year":"2014","unstructured":"Dieci MV, Orvieto E, Dominici M et al (2014) Rare breast cancer subtypes: histological, molecular, and clinical peculiarities. Oncologist 19:805\u2013813. doi: 10.1634\/theoncologist.2014-0108","journal-title":"Oncologist"},{"key":"3682_CR17","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s10549-013-2740-6","volume":"142","author":"HM Horlings","year":"2013","unstructured":"Horlings HM, Weigelt B, Anderson EM et al (2013) Genomic profiling of histological special types of breast cancer. Breast Cancer Res Treat 142:257\u2013269. doi: 10.1007\/s10549-013-2740-6","journal-title":"Breast Cancer Res Treat"},{"key":"3682_CR18","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/path.2763","volume":"222","author":"M Lacroix-Triki","year":"2010","unstructured":"Lacroix-Triki M, Suarez PH, MacKay A et al (2010) Mucinous carcinoma of the breast is genomically distinct from invasive ductal carcinomas of no special type. J Pathol 222:282\u2013298. doi: 10.1002\/path.2763","journal-title":"J Pathol"},{"key":"3682_CR19","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/path.2974","volume":"226","author":"D Wetterskog","year":"2012","unstructured":"Wetterskog D, Lopez-Garcia MA, Lambros MB et al (2012) Adenoid cystic carcinomas constitute a genomically distinct subgroup of triple-negative and basal-like breast cancers. J Pathol 226:84\u201396. doi: 10.1002\/path.2974","journal-title":"J Pathol"},{"key":"3682_CR20","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/nbt.2696","volume":"31","author":"GM Frampton","year":"2013","unstructured":"Frampton GM, Fichtenholtz A, Otto GA et al (2013) Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 31:1023\u20131031. doi: 10.1038\/nbt.2696","journal-title":"Nat Biotechnol"},{"key":"3682_CR21","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nrc2780","volume":"10","author":"N Turner","year":"2010","unstructured":"Turner N, Grose R (2010) Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 10:116\u2013129. doi: 10.1038\/nrc2780","journal-title":"Nat Rev Cancer"},{"issue":"1263\u20131269","key":"3682_CR22","first-page":"1274","volume":"27","author":"CX Ma","year":"2013","unstructured":"Ma CX, Ellis MJ (2013) The Cancer Genome Atlas: clinical applications for breast cancer. Oncol (Williston Park, NY) 27(1263\u20131269):1274\u20131279","journal-title":"Oncol (Williston Park, NY)"},{"key":"3682_CR23","doi-asserted-by":"crossref","first-page":"R23","DOI":"10.1186\/bcr1665","volume":"9","author":"S Elbauomy Elsheikh","year":"2007","unstructured":"Elbauomy Elsheikh S, Green AR, Lambros MBK et al (2007) FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis. Breast Cancer Res 9:R23. doi: 10.1186\/bcr1665","journal-title":"Breast Cancer Res"},{"key":"3682_CR24","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1158\/1078-0432.CCR-08-1791","volume":"15","author":"F Andre","year":"2009","unstructured":"Andre F, Job B, Dessen P et al (2009) Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array. Clin Cancer Res 15:441\u2013451. doi: 10.1158\/1078-0432.CCR-08-1791","journal-title":"Clin Cancer Res"},{"key":"3682_CR25","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1038\/modpathol.2010.84","volume":"23","author":"CB Moelans","year":"2010","unstructured":"Moelans CB, de Weger RA, Monsuur HN et al (2010) Molecular profiling of invasive breast cancer by multiplex ligation-dependent probe amplification-based copy number analysis of tumor suppressor and oncogenes. Mod Pathol 23:1029\u20131039. doi: 10.1038\/modpathol.2010.84","journal-title":"Mod Pathol"},{"key":"3682_CR26","doi-asserted-by":"crossref","first-page":"647","DOI":"10.3892\/ol.2012.806","volume":"4","author":"M Tiburcio","year":"2012","unstructured":"Tiburcio M, Costa SMA, Fatima Duarte MDE et al (2012) Characterization of PAR1 and FGFR1 expression in invasive breast carcinomas: prognostic significance. Oncol Lett 4:647\u2013657. doi: 10.3892\/ol.2012.806","journal-title":"Oncol Lett"},{"key":"3682_CR27","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1158\/0008-5472.CAN-09-3746","volume":"70","author":"N Turner","year":"2010","unstructured":"Turner N, Pearson A, Sharpe R et al (2010) FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res 70:2085\u20132094. doi: 10.1158\/0008-5472.CAN-09-3746","journal-title":"Cancer Res"},{"key":"3682_CR28","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1158\/1535-7163.MCT-11-0450","volume":"11","author":"JM Gozgit","year":"2012","unstructured":"Gozgit JM, Wong MJ, Moran L et al (2012) Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models. Mol Cancer Ther 11:690\u2013699. doi: 10.1158\/1535-7163.MCT-11-0450","journal-title":"Mol Cancer Ther"},{"key":"3682_CR29","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","volume":"379","author":"WTA Graaf van der","year":"2012","unstructured":"van der Graaf WTA, Blay J-Y, Chawla SP et al (2012) Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Lond Engl 379:1879\u20131886. doi: 10.1016\/S0140-6736(12)60651-5","journal-title":"Lancet Lond Engl"},{"key":"3682_CR30","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1080\/02841860802047411","volume":"47","author":"J Alsner","year":"2008","unstructured":"Alsner J, Jensen V, Kyndi M et al (2008) A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients. Acta Oncol Stockh Swed 47:600\u2013607. doi: 10.1080\/02841860802047411","journal-title":"Acta Oncol Stockh Swed"},{"key":"3682_CR31","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1111\/his.12220","volume":"63","author":"Y Alkam","year":"2013","unstructured":"Alkam Y, Mitomi H, Nakai K et al (2013) Protein expression and methylation of DNA repair genes hMLH1, hMSH2, MGMT and BRCA1 and their correlation with clinicopathological parameters and prognosis in basal-like breast cancer. Histopathology 63:713\u2013725. doi: 10.1111\/his.12220","journal-title":"Histopathology"},{"key":"3682_CR32","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.canlet.2013.08.028","volume":"342","author":"K Uji","year":"2014","unstructured":"Uji K, Naoi Y, Kagara N et al (2014) Significance of TP53 mutations determined by next-generation \u201cdeep\u201d sequencing in prognosis of estrogen receptor-positive breast cancer. Cancer Lett 342:19\u201326. doi: 10.1016\/j.canlet.2013.08.028","journal-title":"Cancer Lett"},{"key":"3682_CR33","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1158\/1078-0432.CCR-05-1029","volume":"12","author":"M Olivier","year":"2006","unstructured":"Olivier M, Langer\u00f8d A, Carrieri P et al (2006) The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res 12:1157\u20131167. doi: 10.1158\/1078-0432.CCR-05-1029","journal-title":"Clin Cancer Res"},{"key":"3682_CR34","doi-asserted-by":"crossref","first-page":"e55103","DOI":"10.1371\/journal.pone.0055103","volume":"8","author":"F V\u00e9gran","year":"2013","unstructured":"V\u00e9gran F, Rebucci M, Chevrier S et al (2013) Only missense mutations affecting the DNA binding domain of p53 influence outcomes in patients with breast carcinoma. PLoS One 8:e55103. doi: 10.1371\/journal.pone.0055103","journal-title":"PLoS One"},{"key":"3682_CR35","doi-asserted-by":"crossref","first-page":"D805","DOI":"10.1093\/nar\/gku1075","volume":"43","author":"SA Forbes","year":"2015","unstructured":"Forbes SA, Beare D, Gunasekaran P et al (2015) COSMIC: exploring the world\u2019s knowledge of somatic mutations in human cancer. Nucleic Acids Res 43:D805\u2013D811. doi: 10.1093\/nar\/gku1075","journal-title":"Nucleic Acids Res"},{"key":"3682_CR36","doi-asserted-by":"crossref","first-page":"514","DOI":"10.4161\/cbt.9.7.11115","volume":"9","author":"H Hirai","year":"2010","unstructured":"Hirai H, Arai T, Okada M et al (2010) MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil. Cancer Biol Ther 9:514\u2013522","journal-title":"Cancer Biol Ther"},{"key":"3682_CR37","doi-asserted-by":"crossref","first-page":"5638","DOI":"10.1158\/1078-0432.CCR-11-0650","volume":"17","author":"KA Bridges","year":"2011","unstructured":"Bridges KA, Hirai H, Buser CA et al (2011) MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells. Clin Cancer Res 17:5638\u20135648. doi: 10.1158\/1078-0432.CCR-11-0650","journal-title":"Clin Cancer Res"},{"key":"3682_CR38","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.ccr.2005.05.014","volume":"7","author":"Y Samuels","year":"2005","unstructured":"Samuels Y, Diaz LA, Schmidt-Kittler O et al (2005) Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 7:561\u2013573. doi: 10.1016\/j.ccr.2005.05.014","journal-title":"Cancer Cell"},{"key":"3682_CR39","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/nrc2664","volume":"9","author":"JA Engelman","year":"2009","unstructured":"Engelman JA (2009) Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 9:550\u2013562. doi: 10.1038\/nrc2664","journal-title":"Nat Rev Cancer"},{"key":"3682_CR40","doi-asserted-by":"crossref","first-page":"5049","DOI":"10.1158\/1078-0432.CCR-09-0632","volume":"15","author":"K Kalinsky","year":"2009","unstructured":"Kalinsky K, Jacks LM, Heguy A et al (2009) PIK3CA mutation associates with improved outcome in breast cancer. Clin Cancer Res 15:5049\u20135059. doi: 10.1158\/1078-0432.CCR-09-0632","journal-title":"Clin Cancer Res"},{"key":"3682_CR41","doi-asserted-by":"crossref","first-page":"6064","DOI":"10.1158\/1078-0432.CCR-07-0266","volume":"13","author":"M Barbareschi","year":"2007","unstructured":"Barbareschi M, Buttitta F, Felicioni L et al (2007) Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas. Clin Cancer Res 13:6064\u20136069. doi: 10.1158\/1078-0432.CCR-07-0266","journal-title":"Clin Cancer Res"},{"key":"3682_CR42","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1016\/j.humpath.2012.03.012","volume":"43","author":"EL Kehr","year":"2012","unstructured":"Kehr EL, Jorns JM, Ang D et al (2012) Mucinous breast carcinomas lack PIK3CA and AKT1 mutations. Hum Pathol 43:2207\u20132212. doi: 10.1016\/j.humpath.2012.03.012","journal-title":"Hum Pathol"},{"key":"3682_CR43","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/path.1908","volume":"208","author":"F Buttitta","year":"2006","unstructured":"Buttitta F, Felicioni L, Barassi F et al (2006) PIK3CA mutation and histological type in breast carcinoma: high frequency of mutations in lobular carcinoma. J Pathol 208:350\u2013355. doi: 10.1002\/path.1908","journal-title":"J Pathol"},{"key":"3682_CR44","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1158\/1535-7163.MCT-10-0994","volume":"10","author":"F Janku","year":"2011","unstructured":"Janku F, Tsimberidou AM, Garrido-Laguna I et al (2011) PIK3CA mutations in patients with advanced cancers treated with PI3K\/AKT\/mTOR axis inhibitors. Mol Cancer Ther 10:558\u2013565. doi: 10.1158\/1535-7163.MCT-10-0994","journal-title":"Mol Cancer Ther"},{"key":"3682_CR45","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1109653","volume":"366","author":"J Baselga","year":"2012","unstructured":"Baselga J, Campone M, Piccart M et al (2012) Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366:520\u2013529. doi: 10.1056\/NEJMoa1109653","journal-title":"N Engl J Med"},{"key":"3682_CR46","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/bcr3039","volume":"13","author":"TW Miller","year":"2011","unstructured":"Miller TW, Rexer BN, Garrett JT, Arteaga CL (2011) Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Res 13:224. doi: 10.1186\/bcr3039","journal-title":"Breast Cancer Res"},{"key":"3682_CR47","doi-asserted-by":"crossref","first-page":"e53292","DOI":"10.1371\/journal.pone.0053292","volume":"8","author":"S Loi","year":"2013","unstructured":"Loi S, Michiels S, Baselga J et al (2013) PIK3CA genotype and a PIK3CA mutation-related gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancer. PLoS One 8:e53292. doi: 10.1371\/journal.pone.0053292","journal-title":"PLoS One"},{"key":"3682_CR48","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s10549-013-2529-7","volume":"139","author":"DE Ramirez-Ardila","year":"2013","unstructured":"Ramirez-Ardila DE, Helmijr JC, Look MP et al (2013) Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen. Breast Cancer Res Treat 139:39\u201349. doi: 10.1007\/s10549-013-2529-7","journal-title":"Breast Cancer Res Treat"},{"key":"3682_CR49","doi-asserted-by":"crossref","first-page":"5193","DOI":"10.1038\/onc.2010.257","volume":"29","author":"A Chakrabarty","year":"2010","unstructured":"Chakrabarty A, Rexer BN, Wang SE et al (2010) H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation by heregulin production and activation of HER3. Oncogene 29:5193\u20135203. doi: 10.1038\/onc.2010.257","journal-title":"Oncogene"},{"key":"3682_CR50","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/annonc\/mdp304","volume":"21","author":"Y Kataoka","year":"2010","unstructured":"Kataoka Y, Mukohara T, Shimada H et al (2010) Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines. Ann Oncol 21:255\u2013262. doi: 10.1093\/annonc\/mdp304","journal-title":"Ann Oncol"},{"key":"3682_CR51","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1186\/1471-2407-11-248","volume":"11","author":"L Wang","year":"2011","unstructured":"Wang L, Zhang Q, Zhang J et al (2011) PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib. BMC Cancer 11:248. doi: 10.1186\/1471-2407-11-248","journal-title":"BMC Cancer"},{"key":"3682_CR52","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00428-012-1267-2","volume":"461","author":"M Barbareschi","year":"2012","unstructured":"Barbareschi M, Cuorvo LV, Girlando S et al (2012) PI3KCA mutations and\/or PTEN loss in Her2-positive breast carcinomas treated with trastuzumab are not related to resistance to anti-Her2 therapy. Virchows Arch Int J Pathol 461:129\u2013139. doi: 10.1007\/s00428-012-1267-2","journal-title":"Virchows Arch Int J Pathol"},{"key":"3682_CR53","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/1477-7819-11-139","volume":"11","author":"H-S Tseng","year":"2013","unstructured":"Tseng H-S, Lin C, Chan S-E et al (2013) Pure mucinous carcinoma of the breast: clinicopathologic characteristics and long-term outcome among Taiwanese women. World J Surg Oncol 11:139. doi: 10.1186\/1477-7819-11-139","journal-title":"World J Surg Oncol"},{"key":"3682_CR54","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","volume":"344","author":"DJ Slamon","year":"2001","unstructured":"Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783\u2013792. doi: 10.1056\/NEJM200103153441101","journal-title":"N Engl J Med"},{"key":"3682_CR55","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","volume":"367","author":"S Verma","year":"2012","unstructured":"Verma S, Miles D, Gianni L et al (2012) Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367:1783\u20131791. doi: 10.1056\/NEJMoa1209124","journal-title":"N Engl J Med"},{"key":"3682_CR56","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa1113216","volume":"366","author":"J Baselga","year":"2012","unstructured":"Baselga J, Cort\u00e9s J, Kim S-B et al (2012) Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366:109\u2013119. doi: 10.1056\/NEJMoa1113216","journal-title":"N Engl J Med"},{"key":"3682_CR57","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S1470-2045(13)70130-X","volume":"14","author":"SM Swain","year":"2013","unstructured":"Swain SM, Kim S-B, Cort\u00e9s J et al (2013) Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 14:461\u2013471. doi: 10.1016\/S1470-2045(13)70130-X","journal-title":"Lancet Oncol"},{"key":"3682_CR58","doi-asserted-by":"crossref","first-page":"e88","DOI":"10.1200\/JCO.2013.49.0599","volume":"32","author":"SM Ali","year":"2014","unstructured":"Ali SM, Alpaugh RK, Downing SR et al (2014) Response of an ERBB2-mutated inflammatory breast carcinoma to human epidermal growth factor receptor 2-targeted therapy. J Clin Oncol 32:e88\u2013e91. doi: 10.1200\/JCO.2013.49.0599","journal-title":"J Clin Oncol"},{"key":"3682_CR59","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1007\/s00280-013-2262-2","volume":"72","author":"RC Jankowitz","year":"2013","unstructured":"Jankowitz RC, Abraham J, Tan AR et al (2013) Safety and efficacy of neratinib in combination with weekly paclitaxel and trastuzumab in women with metastatic HER2-positive breast cancer: an NSABP Foundation Research Program phase I study. Cancer Chemother Pharmacol 72:1205\u20131212. doi: 10.1007\/s00280-013-2262-2","journal-title":"Cancer Chemother Pharmacol"},{"key":"3682_CR60","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1016\/j.ejca.2013.07.142","volume":"49","author":"M Martin","year":"2013","unstructured":"Martin M, Bonneterre J, Geyer CE et al (2013) A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer. Eur J Cancer Oxf Engl 49:3763\u20133772. doi: 10.1016\/j.ejca.2013.07.142","journal-title":"Eur J Cancer Oxf Engl"},{"key":"3682_CR61","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1158\/2159-8290.CD-12-0349","volume":"3","author":"R Bose","year":"2013","unstructured":"Bose R, Kavuri SM, Searleman AC et al (2013) Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov 3:224\u2013237. doi: 10.1158\/2159-8290.CD-12-0349","journal-title":"Cancer Discov"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-016-3682-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-016-3682-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-016-3682-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T19:56:28Z","timestamp":1718308588000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-016-3682-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":61,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["3682"],"URL":"https:\/\/doi.org\/10.1007\/s10549-016-3682-6","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1]]}}}